Leila Jamal1, Jill O Robinson2, Kurt D Christensen3, Jennifer Blumenthal-Barby2, Melody J Slashinski4, Denise Lautenbach Perry5, Jason L Vassy6, Julia Wycliff2, Robert C Green7, Amy L McGuire2. 1. a Center for Medical Ethics and Health Policy, Baylor College of Medicine, and Johns Hopkins Berman Institute of Bioethics , Johns Hopkins University. 2. b Center for Medical Ethics and Health Policy , Baylor College of Medicine. 3. c Department of Medicine , Brigham and Women's Hospital. 4. d School of Public Health and Health Sciences , University of Massachusetts. 5. e Division of Genetics, Department of Medicine , Brigham and Women's Hospital. 6. f Division of General Medicine and Primary Care , Brigham and Women's Hospital, Section of General Internal Medicine, VA Boston Healthcare System, and Harvard Medical School. 7. g Division of Genetics, Department of Medicine , Brigham and Women's Hospital, and Harvard Medical School.
Abstract
BACKGROUND: Clinical genome and exome sequencing (CGES) is being used in an expanding range of clinical settings. Most approaches to offering patients choices about learning CGES results classify results according to expert definitions of clinical actionability. Little is known about how patients conceptualize different categories of CGES results. METHODS: The MedSeq Project is a randomized controlled trial studying the use of whole-genome sequencing (WGS) in primary care and cardiology. We surveyed 202 patient-participants about different kinds of WGS results and conducted qualitative interviews with 49 of these participants. Interview data were analyzed both inductively and deductively using thematic content analysis. RESULTS: Participants demonstrated high levels of study understanding and genetic literacy. A small majority of participants wanted to learn all of their WGS results (n = 123, 61%). Qualitative data provided a deeper understanding of participants' perspectives about different types of WGS results. Participants did not have the same views about which WGS results would be actionable or upsetting to learn. They conceptualized variants of uncertain significance (VUS) in a variety of different ways. Many participants expressed optimism that the uncertainty associated with VUS results could be reduced over time. CONCLUSIONS: Proposals to determine which WGS/CGES results to disclose by soliciting patient preferences may fail to appreciate the complex ways patients think about disease and the information WGS/CGES can produce. Our findings challenge prevailing methods of facilitating patient choice and assessing the benefits and harms related to the return of WGS/CGES results, which mostly rely on expert definitions of clinical utility to categorize the kinds of results patients can learn.
RCT Entities:
BACKGROUND: Clinical genome and exome sequencing (CGES) is being used in an expanding range of clinical settings. Most approaches to offering patients choices about learning CGES results classify results according to expert definitions of clinical actionability. Little is known about how patients conceptualize different categories of CGES results. METHODS: The MedSeq Project is a randomized controlled trial studying the use of whole-genome sequencing (WGS) in primary care and cardiology. We surveyed 202 patient-participants about different kinds of WGS results and conducted qualitative interviews with 49 of these participants. Interview data were analyzed both inductively and deductively using thematic content analysis. RESULTS:Participants demonstrated high levels of study understanding and genetic literacy. A small majority of participants wanted to learn all of their WGS results (n = 123, 61%). Qualitative data provided a deeper understanding of participants' perspectives about different types of WGS results. Participants did not have the same views about which WGS results would be actionable or upsetting to learn. They conceptualized variants of uncertain significance (VUS) in a variety of different ways. Many participants expressed optimism that the uncertainty associated with VUS results could be reduced over time. CONCLUSIONS: Proposals to determine which WGS/CGES results to disclose by soliciting patient preferences may fail to appreciate the complex ways patients think about disease and the information WGS/CGES can produce. Our findings challenge prevailing methods of facilitating patient choice and assessing the benefits and harms related to the return of WGS/CGES results, which mostly rely on expert definitions of clinical utility to categorize the kinds of results patients can learn.
Authors: Laura M Amendola; Jonathan S Berg; Carol R Horowitz; Frank Angelo; Jeannette T Bensen; Barbara B Biesecker; Leslie G Biesecker; Gregory M Cooper; Kelly East; Kelly Filipski; Stephanie M Fullerton; Bruce D Gelb; Katrina A B Goddard; Benyam Hailu; Ragan Hart; Kristen Hassmiller-Lich; Galen Joseph; Eimear E Kenny; Barbara A Koenig; Sara Knight; Pui-Yan Kwok; Katie L Lewis; Amy L McGuire; Mary E Norton; Jeffrey Ou; Donald W Parsons; Bradford C Powell; Neil Risch; Mimsie Robinson; Christine Rini; Sarah Scollon; Anne M Slavotinek; David L Veenstra; Melissa P Wasserstein; Benjamin S Wilfond; Lucia A Hindorff; Sharon E Plon; Gail P Jarvik Journal: Am J Hum Genet Date: 2018-09-06 Impact factor: 11.025
Authors: Kristin Clift; Sarah Macklin; Colin Halverson; Jennifer B McCormick; Abd Moain Abu Dabrh; Stephanie Hines Journal: J Community Genet Date: 2019-08-20
Authors: Steven Joffe; Deborah E Sellers; Lynette Ekunwe; Donna Antoine-Lavigne; Sarah McGraw; Daniel Levy; Greta Lee Splansky Journal: Circ Genom Precis Med Date: 2019-11-22
Authors: Christin Hoell; Julia Wynn; Luke V Rasmussen; Keith Marsolo; Sharon A Aufox; Wendy K Chung; John J Connolly; Robert R Freimuth; David Kochan; Hakon Hakonarson; Margaret Harr; Ingrid A Holm; Iftikhar J Kullo; Philip E Lammers; Kathleen A Leppig; Nancy D Leslie; Melanie F Myers; Richard R Sharp; Maureen E Smith; Cynthia A Prows Journal: Genet Med Date: 2020-07-16 Impact factor: 8.864
Authors: G Lázaro-Muñoz; M S Farrell; J J Crowley; D M Filmyer; R A Shaughnessy; R C Josiassen; P F Sullivan Journal: Mol Psychiatry Date: 2017-11-21 Impact factor: 15.992